Aytu Biopharma (AYTU) Liabilities and Shareholders Equity (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $111.7 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 10.07% year-over-year to $111.7 million in Q1 2026; TTM through Mar 2026 was $482.9 million, a 1.79% increase from a year earlier, with the FY2025 full-year figure at $124.2 million, up 5.15% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $111.7 million, down from $122.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for AYTU reached as high as $168.8 million in Q1 2022 and fell as low as $111.7 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $131.3 million across 5 years, with a median of $128.9 million in 2024.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 113206.04% in 2022 and fell as far as 48.2% in 2022.
• Year by year, Liabilities and Shareholders Equity stood at $141.4 million in 2022, then declined by 7.2% to $131.2 million in 2023, then slipped by 11.45% to $116.2 million in 2024, then grew by 4.97% to $122.0 million in 2025, then slipped by 8.45% to $111.7 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $111.7 million in Q1 2026, $122.0 million in Q4 2025, and $125.0 million in Q3 2025.